Milan, Italy, Sept. 30, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central nervous system (CNS) and pain therapies, and
Milan, Italy – September 15, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a research and development company focused on novel central nervous system (CNS) and pain
Milan, Italy – July 14, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central nervous system (CNS) and pain therapies, today
Milan, Italy – June 25, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announces that it has received
Germany is the first country in which Xadago® is available as an add-on to levodopa alone and in combination with other PD medications
Milan – May 15, 2015 – Zambon S.p.A., an
- Funding Set to Accelerate Clinical Development of Novel Medicines for Rare Central Nervous System Disorders -
Milan, Italy – April 30, 2015 – Newron Pharmaceuticals S.p.A. (“
Milan, Italy – 24 March 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel Central Nervous System (CNS) and pain therapies,
March 4, 2015 – Milan, Italy – Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS) and
Milan, Italy – March 4, 2015 - Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel Central Nervous System (CNS) and pain therapies,
Xadago® under review as an add-on therapy for patients with early- to late-stage Parkinson’s disease
PDUFA date by December 29, 2015
Milan, Italy, March 2, 2015 – Newron
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
